scPharmaceuticals Inc (FRA:2SX)
€ 3.34 -0.12 (-3.47%) Market Cap: 176.08 Mil Enterprise Value: 139.10 Mil PE Ratio: 0 PB Ratio: 6.04 GF Score: 28/100

scPharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 16, 2023 / 04:20PM GMT
Release Date Price: €8.35 (+12.84%)
Roanna Ruiz
SVB Securities - Analyst

Great. Welcome back, everyone, to the next session. And apologies, we had a couple of technical issues, but we are back. So I'm Roanna Ruiz, senior biotech analyst here at SVB Securities, and it's my pleasure to introduce the management team of scPharmaceuticals. We have John Tucker, CEO; and we also have John Mohr, SVP of Clinical Development.

So welcome both of you, and I will pass it to John for a presentation of the company.

John Tucker
scPharmaceuticals Inc. - President & CEO

Great, Roanna. Thank you so much, and welcome, everyone. Typical forward-looking statements.

So today, I'll be quick. A quick overview on the company and then a disease overview and talk about FUROSCIX, where we're on the verge of launching and incredibly excited. And I'd spend a little bit of time on the commercial opportunity.

So company highlights. ScPharmaceuticals, the name really says what we do. We take drugs that are already in the hospital being delivered IV, and create new formulations, new delivery

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot